BioPharma Dive April 30, 2024
Large and small drugmakers are vying for a piece of what analysts view as one of the biggest market opportunities in the pharma industry’s history. Here’s what’s coming next.
One study can start a pharmaceutical revolution.
Four years ago, a large clinical trial run by Novo Nordisk showed a drug called semaglutide helped people with obesity lose, on average, around 15% of their weight. The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a rush to research that has quickly reshaped the obesity drug field.
Demand for semaglutide, now sold in nine countries by Novo as Wegovy, has surged to such heights the company can’t keep up. Physicians see Wegovy and other drugs...
Today's Sponsors
Today's Sponsor